This article is more than 5 years old. Information may no longer be current.

Nasdaq to delist Affymax

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

On May 28, Affymax Inc. received a determination letter from Nasdaq indicating that Nasdaq believes that the company should be delisted, Affymax announced in a regulatory filing. Specifically, Nasdaq said that Affymax is operating as a “public shell” and following the voluntary recall of Omontys, the company no longer has an operating business.

Affymax said in the filing that it does not plan to appeal the determination by Nasdaq. Trading in the Company’s common stock will be suspended at the opening of business on June 6, 2013.